Enveda raises $311M to advance more AI-driven natural product drugs into clinical testing

Enveda, a biotech startup applying artificial intelligence to uncover new medicines from the natural world, has closed a $311 million Series E round at a $2 billion valuation. The funding was led by Catalio Capital Management, with Iconiq joining as a participant alongside other investors. The figure marks a doubling of the valuation the company secured just 12 months ago, underscoring how quickly investor confidence in AI-driven drug discovery is growing.

Why Natural Products, Not Lab Synthesis

The core premise behind Enveda is that some of the most powerful medicines may already exist in plants and microbes, rather than needing to be built from scratch in a laboratory. Founded in 2019 by Viswa Colluru, an early employee at Recursion Pharmaceuticals, the company uses AI and complementary techniques to accelerate the identification and development of these naturally derived drug candidates. By decoding the chemistry of the natural world at scale, Enveda aims to shorten a discovery process that has traditionally taken years.

Moving Candidates Into Human Trials

Although no AI-discovered drug has yet earned FDA approval, Enveda sits within a wave of companies pushing AI-identified candidates into human clinical trials. The startup currently has several drugs being tested in patients. Among them is one treatment aimed at severe skin conditions and another designed to help patients maintain weight loss after they stop taking GLP-1 medications.

What to Watch Next

Enveda's rapid valuation climb reflects mounting interest in AI-powered biotech, even as the industry awaits proof that machine-discovered compounds can clear regulatory hurdles. Progress in the company's clinical programs—and whether any AI-discovered candidate eventually wins FDA approval—will be closely watched across the sector.